{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:54:47Z","timestamp":1789941287369,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["2015\/19\/B\/NZ7\/03543"],"award-info":[{"award-number":["2015\/19\/B\/NZ7\/03543"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.neuropharm.2017.07.022","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T04:17:23Z","timestamp":1500956243000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain"],"prefix":"10.1016","volume":"125","author":[{"given":"Kinga","family":"Sa\u0142at","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Furga\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rojek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"\u015aniecikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.07.022_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0022-3565(25)38088-2","article-title":"Differential roles of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor subtypes in modulating spinal nociceptive transmission in mice","volume":"265","author":"Alhaider","year":"1993","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-8993(94)91184-3","article-title":"The actions of 5-HT1 agonists and antagonists on nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies","volume":"661","author":"Ali","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1248\/bpb.b13-00735","article-title":"Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats","volume":"37","author":"Aoki","year":"2014","journal-title":"Biol. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.neuropharm.2017.07.022_bib4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Assi\u00e9","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FBP.0b013e328349aae4","article-title":"The complex role of serotonin and 5-HT receptors in chronic pain","volume":"22","author":"Bardin","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejpain.2003.09.002","article-title":"Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats","volume":"8","author":"Bardin","year":"2004","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000068404","article-title":"Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain","volume":"67","author":"Bardin","year":"2003","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejphar.2014.11.046","article-title":"The pain of pain: challenges of animal behavior models","volume":"753","author":"Barrett","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2013.03.003","article-title":"Targeting TRP channels for pain relief","volume":"716","author":"Brederson","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(03)01566-8","article-title":"Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640","volume":"466","author":"Bruins Slot","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2005.03.016","article-title":"Effects of the high-efficacy 5-HT1A receptor agonist, F 13640 in the formalin pain model: a c-Fos study","volume":"514","author":"Buritova","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2004.06.026","article-title":"High-efficacy 5-HT1A receptor activation causes a curative-like action on allodynia in rats with spinal cord injury","volume":"497","author":"Colpaert","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0304-3940(87)90218-7","article-title":"Autoradiographic evidence of serotonin1 binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord","volume":"83","author":"Daval","year":"1987","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(02)02640-7","article-title":"The 5-HT(1A) receptor agonist F 13640 attenuates mechanical allodynia in a rat model of trigeminal neuropathic pain","volume":"456","author":"Deseure","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ejpain.2004.01.002","article-title":"Effects of the combined continuous administration of morphine and the high-efficacy 5-HT1A agonist, F 13640 in a rat model of trigeminal neuropathic pain","volume":"8","author":"Deseure","year":"2004","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3565(25)05180-8","article-title":"Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines","volume":"107","author":"Eddy","year":"1953","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib18","unstructured":"Eu Clinical Trials Register, 2017. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-012123-28\/FR (accessed 24.05.17)."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropathic pain treatment: an evidence based proposal","volume":"118","author":"Finnerup","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1155\/2003\/236718","article-title":"Methadone in the treatment of neuropathic pain","volume":"8","author":"Gagnon","year":"2003","journal-title":"Pain Res. Manag."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(09)61081-3","article-title":"Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial","volume":"374","author":"Gilron","year":"2009","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0304-3959(87)90088-1","article-title":"The formalin test in mice: dissociation between inflammatory and non-inflammatory pain","volume":"30","author":"Hunskaar","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2005.09.003","article-title":"The novel analgesic, F 13640, produces intra- and postoperative analgesia in a rat model of surgical pain","volume":"523","author":"Kiss","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1476-5381.2009.00249.x","article-title":"5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception","volume":"158","author":"Martel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrn2606","article-title":"Animal models of pain: progress and challenges","volume":"10","author":"Mogil","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/bja\/88.5.679","article-title":"Antinociceptive role of 5-HT1A receptors in rat spinal cord","volume":"88","author":"Nadeson","year":"2002","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib29","first-page":"638","article-title":"Diabetic painful and insensate neuropathy: pathogenesis and potential treatments","volume":"6","author":"Obrosova","year":"2009","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12990-015-0026-1","article-title":"Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"11","author":"Park","year":"2015","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0006-3223(85)90194-5","article-title":"Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors","volume":"20","author":"Peroutka","year":"1985","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib32","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/cddis.2011.98","article-title":"Anatomical study of serotonergic innervation and 5-HT(1A) receptor in the human spinal cord","volume":"2","author":"Perrin","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00210-013-0847-2","article-title":"Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice","volume":"386","author":"Sa\u0142at","year":"2013","journal-title":"Naunyn. Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1254\/jphs.08032FP","article-title":"Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy","volume":"107","author":"Tanabe","year":"2008","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","article-title":"The formalin test: an evaluation of the method","volume":"51","author":"Tj\u00f8lsen","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib37","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pbb.2012.05.006","article-title":"5-HT7 receptor activation attenuates thermal hyperalgesia in streptozocin-induced diabetic mice","volume":"102","author":"Ulugol","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2003.08.047","article-title":"The very-high-efficacy 5-HT1A receptor agonist, F 13640, preempts the development of allodynia-like behaviors in rats with spinal cord injury","volume":"478","author":"Wu","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.07.022_bib42","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0022-3565(25)38857-9","article-title":"Serotonin receptor subtypes in spinal antinociception in the rat","volume":"269","author":"Xu","year":"1994","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1090-3801(98)90047-7","article-title":"Influence of formalin concentration on the antinociceptive effects of anti-inflammatory drugs in the formalin test in rats: separate mechanisms underlying the nociceptive effects of low- and high-concentration formalin","volume":"2","author":"Yashpal","year":"1998","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.expneurol.2004.08.031","article-title":"The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes","volume":"191","author":"You","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.07.022_bib45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3959(01)00259-7","article-title":"The role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptors in modulating spinal nociceptive transmission in normal and carrageenan-injected rats","volume":"92","author":"Zhang","year":"2001","journal-title":"Pain"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:42:35Z","timestamp":1750786955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817303532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":45,"alternative-id":["S0028390817303532"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.07.022","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}